Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Phone Reviews
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Phone Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / After setback, Serum allowed to resume Oxford's coronavirus vaccine trial
  • India

    After setback, Serum allowed to resume Oxford's coronavirus vaccine trial

    Shalini Ojha
    Written by
    Shalini Ojha
    Twitter
    Last updated on Sep 16, 2020, 10:17 am
    After setback, Serum allowed to resume Oxford's coronavirus vaccine trial
  • Drugs Controller General of India (DCGI) Dr. VG Somani has permitted the Serum Institute of India (SII) to resume trial of the coronavirus vaccine candidate, being developed by the University of Oxford, revoking the last week's order that halted the process.

    The Pune-based firm was, however, directed to take extra precautions.

    Effectively, the order directing SII to stop recruitment of candidates was also withdrawn.

  • In this article
    SII approached DCGI seeking permission, regulator accepted request Resume trial, but follow conditions: DCGI to SII Within a week, AstraZeneca paused and resumed late-stage vaccine trial The vaccine was found to be effective in earlier stages SII has signed a deal to mass produce the vaccine Don't see a plan to distribute vaccines in India: Poonawalla
  • Series of events

    SII approached DCGI seeking permission, regulator accepted request

    SII approached DCGI seeking permission, regulator accepted request
  • DCGI's Tuesday permission came after SII furnished recommendations of the Data Safety Monitoring Board in the UK and India, as demanded by the regulator earlier, and sought approval for re-starting recruitment for the phase 2 and phase 3 trials.

    Dr. Somani in its reply to SII said the letter was "carefully examined." While giving the requisite permission, DCGI asked SII to submit medication details.

  • Letter

    Resume trial, but follow conditions: DCGI to SII

    Resume trial, but follow conditions: DCGI to SII
  • In the order, DCGI told SII it can recommence the trial dated August 2, 2020, according to the already approved protocol and under the provisions of New Drugs and Clinical Trials Rules, 2019.

    The regulator also asked SII to scrupulously follow conditions "such as extra care during screening, additional information in the informed consent, and close monitoring for similar events during the study follow-up."

  • Looking back

    Within a week, AstraZeneca paused and resumed late-stage vaccine trial

  • This order comes close to heels of a similar directive in the United Kingdom, which allowed pharma-giant AstraZeneca to resume the late-stage trial.

    The UK-based company suspended tests last week after a woman developed an "adverse reaction" to the AZD1222 vaccine, which has given a coronavirus-battered globe much-needed hope.

    AstraZeneca, which is developing the vaccine with Oxford, assured that it won't compromise on safety.

  • Vaccine

    The vaccine was found to be effective in earlier stages

  • The potential vaccine consists of the replication-deficient chimpanzee viral vector (ChAdOx1) based on a weakened version of a common cold virus (adenovirus) containing the genetic material of the SARS-CoV-2 virus spike protein.

    In the early-stage examination, it was found that the vaccine provides double-protection against the highly-contagious disease, by generating neutralizing antibodies against SARS-CoV-2 and also producing sufficient levels of virus-attacking T-cells.

  • Details

    SII has signed a deal to mass produce the vaccine

  • As Oxford's vaccine candidate reflected promising results, several companies, like SII, signed deals for mass production of doses.

    Adar Poonawalla, who is at the helm of SII, had earlier said the vaccine would be available in India by the 2021's first quarter.

    However, recently, he said that in the absence of a system to safely transport vaccines to 1.4 billion people, India might suffer.

  • Quote

    Don't see a plan to distribute vaccines in India: Poonawalla

  • "I still don't see a proper plan to do that (distribute vaccine) beyond 400 million doses. You don't want a situation with the vaccine where you have the capacity for your country but you can't consume it," he said in an interview with Financial Times.

  • Oxford
  • United Kingdom
  • University of Oxford
  • Financial Times
  • Coronavirus
  •  
Latest News
  • 'Lut Gaye': Hashmi's song crosses 500mn views in 60 days
    'Lut Gaye': Hashmi's song crosses 500mn views in 60 days
    Entertainment
  • Kafeel Khan urges government to let him serve during COVID-19
    Kafeel Khan urges government to let him serve during COVID-19
    India
  • Bharat Biotech to produce 700 million COVAXIN doses per year
    Bharat Biotech to produce 700 million COVAXIN doses per year
    India
  • Delhi CM Arvind Kejriwal isolates after wife tests COVID-positive
    Delhi CM Arvind Kejriwal isolates after wife tests COVID-positive
    India
  • 2,700 beds for COVID-19 patients will be added in Delhi
    2,700 beds for COVID-19 patients will be added in Delhi
    Delhi
Related Timelines
  • SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    India
  • India could start 2021 with COVID-19 vaccine in hand: DCGI
    India could start 2021 with COVID-19 vaccine in hand: DCGI
    India
  • SII says Covishield 'safe' after trial participant sends legal notice
    SII says Covishield 'safe' after trial participant sends legal notice
    Science
  • SII to sue vaccine trial participant for Rs. 100 crore
    SII to sue vaccine trial participant for Rs. 100 crore
    Science
Trending Topics
ISRO Vaccine
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Samsung Virat Kohli Rohit Sharma
Cricket News Qualcomm YouTube Hollywood News WhatsApp Bollywood News ISRO Spotify SpaceX Yoga
Honda Batman Football News BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Apple Royal Challengers Bangalore
Toyota Fashion Tips Manmohan Singh Sensex Mercedes Taylor Swift Sidharth Malhotra Isha Ambani India Vs England Cricket OnePlus Mobiles
Android TV Smart TV Marvel Comics Avengers
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021